[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604947":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":150,"collaborators":20,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":20,"eligibilityCriteria":158,"healthyVolunteers":154,"sex":159,"minAge":160,"maxAge":20,"enrollmentInfo":161,"targetDuration":20,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Immunocore Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: IMC-P115C Monotherapy","EXPERIMENTAL","Participants receive IMC-P115C intravenous (IV) infusion",[13],"Drug: IMC-P115C",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","IMC-P115C","IV infusion",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Immunocore Medical Information Global","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",[32,45,54,63,74,83,92,103,109,118,129,135,144],{"facility":33,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":20},"Cancer Research South Australia (CRSA)","RECRUITING","Adelaide","5000","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],138.59863,-34.92866,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":20,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":20},"Linear Clinical Research ltd.","Nedlands","06009",{"type":40,"coordinates":50},[51,52],115.8073,-31.98184,{"lat":52,"lon":51},{"facility":55,"status":34,"city":56,"state":20,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":20},"Melanoma Institute Australia","Wollstonecraft","2065",{"type":40,"coordinates":59},[60,61],151.18981,-33.8328,{"lat":61,"lon":60},{"facility":64,"status":34,"city":65,"state":20,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":20},"UNICANCER - Centre Leon-Berard (CLB)","Lyon","69008","France","FR",{"type":40,"coordinates":70},[71,72],4.84789,45.74906,{"lat":72,"lon":71},{"facility":75,"status":34,"city":76,"state":20,"zip":77,"country":67,"countryCode":68,"cosmosGeoPoint":78,"geoPoint":82,"contacts":20},"Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)","Toulouse","31059",{"type":40,"coordinates":79},[80,81],1.44367,43.60426,{"lat":81,"lon":80},{"facility":84,"status":34,"city":85,"state":20,"zip":86,"country":67,"countryCode":68,"cosmosGeoPoint":87,"geoPoint":91,"contacts":20},"Institut Gustave Roussy","Villejuif","94805",{"type":40,"coordinates":88},[89,90],2.35992,48.7939,{"lat":90,"lon":89},{"facility":93,"status":34,"city":94,"state":20,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":20},"Fondazione IRCCS - Istituto Nazionale dei Tumori","Milan","20133","Italy","IT",{"type":40,"coordinates":99},[100,101],12.59836,42.78235,{"lat":101,"lon":100},{"facility":104,"status":34,"city":94,"state":20,"zip":105,"country":96,"countryCode":97,"cosmosGeoPoint":106,"geoPoint":108,"contacts":20},"Istituto Europeo di Oncologia","20141",{"type":40,"coordinates":107},[100,101],{"lat":101,"lon":100},{"facility":110,"status":34,"city":111,"state":20,"zip":112,"country":96,"countryCode":97,"cosmosGeoPoint":113,"geoPoint":117,"contacts":20},"Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\"","Naples","80131",{"type":40,"coordinates":114},[115,116],14.26811,40.85216,{"lat":116,"lon":115},{"facility":119,"status":34,"city":120,"state":20,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":20},"Hospital Universitari Vall d Hebron","Barcelona","08035","Spain","ES",{"type":40,"coordinates":125},[126,127],2.15899,41.38879,{"lat":127,"lon":126},{"facility":130,"status":34,"city":120,"state":20,"zip":131,"country":122,"countryCode":123,"cosmosGeoPoint":132,"geoPoint":134,"contacts":20},"Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals","08908",{"type":40,"coordinates":133},[126,127],{"lat":127,"lon":126},{"facility":136,"status":34,"city":137,"state":20,"zip":138,"country":122,"countryCode":123,"cosmosGeoPoint":139,"geoPoint":143,"contacts":20},"Hospital Universitario Ramon y Cajal","Madrid","28034",{"type":40,"coordinates":140},[141,142],-3.70256,40.4165,{"lat":142,"lon":141},{"facility":145,"status":34,"city":137,"state":20,"zip":146,"country":122,"countryCode":123,"cosmosGeoPoint":147,"geoPoint":149,"contacts":20},"START Madrid - Hospital Universitario Fundación Jiménez Díaz","28040",{"type":40,"coordinates":148},[141,142],{"lat":142,"lon":141},{"type":151,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100604947","phase-1-study-of-imc-p115c-in-advanced-prame-positive-cancers-100604947",false,"NCT07156136","Study of IMC-P115C in Advanced PRAME-Positive Cancers","A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* HLA-A\\*02:01-positive\n* Meeting PRAME-positive tumor testing requirements\n* Metastatic or unresectable solid tumors\n* Have received (or be receiving), relapsed from, be refractory to or intolerant of all therapies\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* Symptomatic or untreated central nervous system metastasis\n* Bowel obstruction, perforation, or fistula formation within 3 months prior to the planned first dose of study treatment\n* Ongoing ascites or effusion requiring recent drainages\n* Significant ongoing toxicity from prior anticancer treatment\n* Out-of-range laboratory values\n* Clinically significant lung, heart, or autoimmune disease\n* Ongoing requirement for immunosuppressive treatment\n* Significant secondary malignancy\n* Hypersensitivity to study drug or excipients\n* Pregnant or lactating","ALL","18 Years",{"count":162,"type":163},140,"ESTIMATED","INTERVENTIONAL",[166],"PHASE1","Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.",[169,170,171],"PRAME Positive","Cancer","HLA-A*02:01-positive",[173],"PRAME","2026-02-23",{"date":176,"type":177},"2026-02-25","ACTUAL",{"date":179,"type":177},"2024-11-07",{"date":181,"type":163},"2029-08-30",{"name":5,"class":6},13]